Polyhydroxyalkylammonium Sodium Channel Blocker for Mucosal Hydration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for chronic bronchitis, COPD, and cystic fibrosis focus on treating symptoms rather than the fundamental issue of mucus clearance failure, with existing sodium channel blockers being impotent, rapidly absorbed, and having short half-lives on mucosal surfaces.
Innovation Solution
Development of the compound 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide, which acts as a potent sodium channel blocker with a longer half-life and improved efficacy on mucosal tissues, reducing water absorption and increasing protective liquid levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing sodium channel blockers are used to treat mucosal surface diseases, then Na+ absorption is blocked, but the compounds are rapidly absorbed and have short half-lives on mucosal surfaces
Solution Approach 1:
The patent modifies the chemical structure of sodium channel blockers by introducing a polyhydroxyalkylammonium group (specifically hexyl(2,3,4,5,6-pentahydroxyhexyl)amino) attached to the pyrazine core. This structural parameter change increases the molecular weight and adds hydrophilic character, which reduces rapid absorption and extends the half-life on mucosal surfaces while maintaining therapeutic efficacy.
Solution Approach 2:
The invention creates a composite molecular structure combining the pyrazine carboxamide core (providing sodium channel blocking activity) with a polyhydroxyalkylammonium side chain (providing extended residence time). This composite structure integrates two functional elements: the pharmacophore for ENaC blockade and the hydrophilic moiety for reduced absorption and extended duration of action.
2Reliability
If existing sodium channel blockers are used, then some therapeutic effect is achieved, but the compounds are impotent and require high doses
Solution Approach 1:
The patent optimizes the substitution pattern on the pyrazine ring, specifically placing amino groups at positions 3 and 5, and a chlorine atom at position 6. This parameter optimization enhances the binding affinity to the epithelial sodium channel (ENaC), increasing potency and reducing the dose required for therapeutic effect.
3Quantity of substance
If the liquid layer on mucosal surfaces is increased to improve protective mechanisms, then hydration is improved, but Na+ absorption must be blocked
Solution Approach 1:
The patent designs the compound to act locally at the apical membrane of epithelial cells where ENaC channels are located. The bulky hydrophilic side chain anchors the molecule to the mucosal surface, creating a localized effect that blocks Na+ absorption at the target site without systemic absorption, thereby reducing the risk of hyperkalemia while increasing local liquid layer quantity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively increases mucosal hydration, rebalances the liquid layer on mucosal surfaces, and minimizes the onset or progression of hyperkalemia, providing a more potent treatment for diseases associated with mucus clearance failure.
Implementation Method 1
The use of ENaC blockers has been reported for a variety of diseases which are ameliorated by increased mucosal hydration... an ENaC blocker of the amiloride class will be delivered to the mucosal surface and maintained at this site to achieve maximum therapeutic benefit
Data Source
AI summary
The present invention relates to the compound of the formula:or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.